Intrexon Corp. (NYSE:XON) shares traded down 7.2% during trading on Tuesday . The company traded as low as $23.61 and last traded at $23.61, with a volume of 702,962 shares changing hands. The stock had previously closed at $25.45.

A number of research analysts have recently commented on the company. JMP Securities reissued a “buy” rating on shares of Intrexon Corp. in a report on Sunday. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a report on Tuesday. Griffin Securities reissued a “buy” rating and set a $65.00 price objective on shares of Intrexon Corp. in a report on Tuesday, June 7th. Wunderlich reissued a “buy” rating and set a $50.00 price objective on shares of Intrexon Corp. in a report on Thursday, July 7th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $57.00 price objective on shares of Intrexon Corp. in a report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $49.66.

The company has a 50 day moving average price of $25.97 and a 200 day moving average price of $29.79. The stock’s market capitalization is $2.73 billion.

Intrexon Corp. (NYSE:XON) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.35. The firm earned $43.40 million during the quarter, compared to the consensus estimate of $46.26 million. Intrexon Corp.’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted $0.25 EPS. Analysts expect that Intrexon Corp. will post ($1.32) earnings per share for the current fiscal year.

In related news, CEO Randal J. Kirk bought 41,830 shares of the stock in a transaction that occurred on Friday, May 13th. The shares were acquired at an average price of $23.92 per share, with a total value of $1,000,573.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Other hedge funds recently added to or reduced their stakes in the company. Profund Advisors LLC increased its stake in Intrexon Corp. by 0.9% in the fourth quarter. Profund Advisors LLC now owns 35,118 shares of the company’s stock worth $1,059,000 after buying an additional 326 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock worth $1,068,000 after buying an additional 880 shares in the last quarter. Bank of Montreal Can increased its stake in Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock worth $1,207,000 after buying an additional 5,742 shares in the last quarter. Rhumbline Advisers increased its stake in Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock worth $1,387,000 after buying an additional 2,890 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Intrexon Corp. by 15.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 50,351 shares of the company’s stock worth $1,518,000 after buying an additional 6,705 shares in the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.